Semma Therapeutics, a Cambridge, MA-based biopharmaceutical company developing cellular therapy for diabetes, accepted a $5m grant from the California Institute of Regenerative Medicine (CIRM).
The award provides funding to develop personalized cell therapy for the treatment of diabetes. Diabetic patients’ own cells will be collected, transformed first into stem cells and then differentiated into stem-cell derived pancreatic islets (SC-islets) to use as an investigational cell therapy for diabetes.
Led by Robert Millman, CEO, Semma Therapeutics leverages technology developed in the lab of Dr. Douglas Melton of Harvard University and licensed by Semma for the development of a cell-based therapy for Type 1 diabetes.
Research is focused on combining proprietary cells with an innovative device to provide a true replacement for the missing islet cells in a diabetic patient without immunosuppression.